Gene therapy for psychiatric disorders.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 23268195.
- Also identified by DOI 10.1016/j.wneu.2012.12.028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Gene therapy has become of increasing interest in clinical neurosurgery with the completion of numerous clinical trials for Parkinson disease, Alzheimer disease, and pediatric genetic disorders. With improved understanding of the dysfunctional circuitry mediating various psychiatric disorders, deep brain stimulation for refractory psychiatric diseases is being increasingly explored in human patients. These factors are likely to facilitate development of gene therapy for psychiatric diseases. Because delivery of gene therapy agents would require the same surgical techniques currently being employed for deep brain stimulation, neurosurgeons are likely to lead the development of this field, as has occurred in other areas of clinical gene therapy for neurologic disorders. We review the current state of gene therapy for psychiatric disorders and focus specifically on particular areas of promising research that may translate into human trials for depression, drug addiction, obsessive-compulsive disorder, and schizophrenia. Issues that are relatively unique to psychiatric gene therapy are also discussed.
Medical subject headings
- Depression
- Depression/psychology
- Depression/therapy
- Genetic Therapy
- Genetic Therapy/methods
- Humans
- Mental Disorders
- Mental Disorders/psychology
- Mental Disorders/therapy
- Obsessive-Compulsive Disorder
- Obsessive-Compulsive Disorder/psychology
- Obsessive-Compulsive Disorder/therapy
- Schizophrenia
- Schizophrenia/therapy
- Schizophrenic Psychology
- Substance-Related Disorders
- Substance-Related Disorders/psychology
- Substance-Related Disorders/therapy